DDD

3D Systems announced the grand opening of its new Industrial Technology Center in Littleton, Colorado, adding 50,000 square feet of manufacturing and office space. The facility strengthens domestic 3D printing production capabilities for aerospace, defense, and semiconductor manufacturers, bringing the company's total advanced manufacturing capacity to approximately 270,000 square feet across Europe and the US. The center maintains critical certifications including ISO9001/AS9100D, ITAR registration, and CMMC Level 2 compliance.

3D Systems announced the grand opening of its new Industrial Technology Center in Littleton, Colorado, adding 50,000 square feet of manufacturing and office space. The expansion strengthens domestic 3D printing production capabilities for aerospace, defense, and semiconductor manufacturers, bringing the company's total advanced manufacturing capacity to approximately 270,000 square feet across Europe and the US. The facility is certified for highly regulated applications and positions 3D Systems to support customers from concept development through qualified production.

IBA announced the first patient treatment in the C-FLASH-01 clinical trial, a groundbreaking feasibility study for ConformalFLASH® proton therapy conducted by Penn Medicine under FDA authorization. The trial evaluates fractioned proton therapy delivered at the Bragg peak for head and neck cancer patients requiring re-irradiation. IBA is actively supporting the clinical evaluation as trial sponsor, partnering with RaySearch Laboratories, 3D Systems, .decimal, and IBA Dosimetry to advance FLASH radiotherapy toward clinical practice.

3D Systems (DDD) has significantly outperformed its Industrial Products sector peers in 2026, returning 101.1% year-to-date compared to the sector average of 15.9%. The company holds a Zacks Rank #2 (Buy) with analyst sentiment improving, as consensus earnings estimates have risen 26.9% over the past 90 days. Eaton (ETN) is also highlighted as another outperforming Industrial Products stock with 35.8% year-to-date returns.

IBA announced the first patient treatment in the C-FLASH-01 clinical trial at Penn Medicine, marking a significant milestone in FLASH proton therapy for head and neck cancer re-irradiation. The trial investigates the feasibility of delivering fractionated ConformalFLASH® proton therapy using Bragg peak proton beams, combining proton therapy's precision with ultra-high dose rate delivery capabilities.